The Safety of Direct Oral Anticoagulants Versus Warfarin Among Older Individuals With Acute Venous Thromboembolism and CKD: A Population-Based Cohort Study

Abstract

Individuals with chronic kidney disease (CKD) have an increased risk of bleeding and thrombosis.1 Although landmark trials of patients with acute venous thromboembolism (VTE) have demonstrated that direct oral anticoagulants (DOACs) are noninferior to vitamin K antagonists with regard to preventing VTE recurrence and the risk of bleeding events, these trials enrolled relatively few patients with CKD.2 Therefore, less information exists on the potential safety concerns associated with VTE treatment strategies in this population.